Show simple item record

Nanomedicines in the treatment of chronic hepatitis C - focus on pegylated interferon alpha-2a

dc.contributor.authorThomas, Ten_US
dc.contributor.authorFoster, Gen_US
dc.date.accessioned2016-10-03T11:30:29Z
dc.date.issued2007en_US
dc.date.submitted2016-09-27T12:57:58.829Z
dc.identifier.issn1176-9114en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/15683
dc.format.extent19 - 24en_US
dc.language.isoenen_US
dc.relation.ispartofINT J NANOMEDen_US
dc.subjectnanomedicinesen_US
dc.subjectnanotechnologyen_US
dc.subjectpegylationen_US
dc.subjectpegylated interferonen_US
dc.subject40 kDa pegylated interferon alpha-2aen_US
dc.subjecthepatitis Cen_US
dc.subjectALPHA-2A PEGASYS(TM)en_US
dc.subjectPEGINTERFERON ALPHA-2Aen_US
dc.subjectUNITED-STATESen_US
dc.subjectEFFICACYen_US
dc.subjectCIRRHOSISen_US
dc.subjectSAFETYen_US
dc.titleNanomedicines in the treatment of chronic hepatitis C - focus on pegylated interferon alpha-2aen_US
dc.typeArticle
dc.rights.holder© 2007 Dove Medical Press Limited
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.volume2en_US


Files in this item

Thumbnail
Name:
Foster Nanomedicines in the ...
Size:
108.2Kb
Format:
application/
Description:
Published version
View/Open

This item appears in the following Collection(s)

Show simple item record